Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
NCT05806164Phase 4Active, not recruiting
- Sponsor
- Women & Infants Hospital
- Start
- Jun 2023
- Primary completion
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of mirabegron, vibegron, botulinum toxin type A in urge incontinence, sponsored by Women & Infants Hospital. Started Jun 2023; status: active, not recruiting.
02
Drugs
mirabegronvibegronbotulinum toxin type A
03
Conditions
urge incontinence
Beyond the preview
Go deeper on NCT05806164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05806164.